Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients
Severe coronavirus disease-19 (COVID-19) has been associated with fibrin-mediated hypercoagulability and thromboembolic complications. To evaluate potential biomarkers of coagulopathy and disease severity in COVID-19, we measured plasma levels of eight biomarkers potentially associated with coagulat...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2022-12, Vol.116 (6), p.937-946 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 946 |
|---|---|
| container_issue | 6 |
| container_start_page | 937 |
| container_title | International journal of hematology |
| container_volume | 116 |
| creator | Cabrera-Garcia, David Miltiades, Andrea Yim, Peter Parsons, Samantha Elisman, Katerina Mansouri, Mohammad Taghi Wagener, Gebhard Harrison, Neil L. |
| description | Severe coronavirus disease-19 (COVID-19) has been associated with fibrin-mediated hypercoagulability and thromboembolic complications. To evaluate potential biomarkers of coagulopathy and disease severity in COVID-19, we measured plasma levels of eight biomarkers potentially associated with coagulation, fibrinolysis, and platelet function in 43 controls and 63 COVID-19 patients, including 47 patients admitted to the intensive care unit (ICU) and 16 non-ICU patients. COVID-19 patients showed significantly elevated levels of fibrinogen, tissue plasminogen activator (t-PA), and its inhibitor plasminogen activation inhibitor 1 (PAI-1), as well as ST2 (the receptor for interleukin-33) and von Willebrand factor (vWF) compared to the control group. We found that higher levels of t-PA, ST2, and vWF at the time of admission were associated with lower survival rates, and that thrombotic events were more frequent in patients with initial higher levels of vWF. These results support a predictive role of specific biomarkers such as t-PA and vWF in the pathophysiology of COVID-19. The data provide support for the case that hypercoagulability in COVID-19 is fibrin-mediated, but also highlights the important role that vWF may play in the genesis of thromboses in the pathophysiology of COVID-19. Interventions designed to enhance fibrinolysis might prove to be useful adjuncts in the treatment of coagulopathy in a subset of COVID-19 patients. |
| doi_str_mv | 10.1007/s12185-022-03437-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9395834</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2890046792</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-f79bcdffff3ceebe228f0e5b39cd0ecb1250ed8febaac6d028999463b45f2b603</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EosvCH-CALHHhEhjbcRxfkNDyValSOQAXDpbtOF2XJF48yaL21-NlS_k44IsP88zM-85LyGMGzxmAeoGMs1ZWwHkFohaq4nfIirWNrIRS9V2yAs1lJRWDE_IA8RKAKajVfXIipNY1a8SKfPkwWBwtdTGNNn8NGalFTD7aOXT0e5y3FJe8j3s7UDt1dN7mNLqEEWmc6DbhLs52iNcF3px_Pn1dMU13do5hmvEhudfbAcOjm39NPr1983Hzvjo7f3e6eXVW-Vq3c9Ur7XzXlyd8CC5w3vYQpBPadxC8Y1xC6No-OGt90wFvdVHfCFfLnrsGxJq8PM7dLW4MnS-7sx3MLsdi6cokG83flSluzUXaGy20bMvl1uTZzYCcvi0BZzNG9GEY7BTSgoYrkEI3mh3Qp_-gl2nJU7Fnii6AulGaF4ofKZ8TYg79rRgG5pCdOWZnSnbmZ3bm0PTkTxu3Lb_CKoA4AlhK00XIv3f_Z-wPBS2nXQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890046792</pqid></control><display><type>article</type><title>Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Cabrera-Garcia, David ; Miltiades, Andrea ; Yim, Peter ; Parsons, Samantha ; Elisman, Katerina ; Mansouri, Mohammad Taghi ; Wagener, Gebhard ; Harrison, Neil L.</creator><creatorcontrib>Cabrera-Garcia, David ; Miltiades, Andrea ; Yim, Peter ; Parsons, Samantha ; Elisman, Katerina ; Mansouri, Mohammad Taghi ; Wagener, Gebhard ; Harrison, Neil L.</creatorcontrib><description>Severe coronavirus disease-19 (COVID-19) has been associated with fibrin-mediated hypercoagulability and thromboembolic complications. To evaluate potential biomarkers of coagulopathy and disease severity in COVID-19, we measured plasma levels of eight biomarkers potentially associated with coagulation, fibrinolysis, and platelet function in 43 controls and 63 COVID-19 patients, including 47 patients admitted to the intensive care unit (ICU) and 16 non-ICU patients. COVID-19 patients showed significantly elevated levels of fibrinogen, tissue plasminogen activator (t-PA), and its inhibitor plasminogen activation inhibitor 1 (PAI-1), as well as ST2 (the receptor for interleukin-33) and von Willebrand factor (vWF) compared to the control group. We found that higher levels of t-PA, ST2, and vWF at the time of admission were associated with lower survival rates, and that thrombotic events were more frequent in patients with initial higher levels of vWF. These results support a predictive role of specific biomarkers such as t-PA and vWF in the pathophysiology of COVID-19. The data provide support for the case that hypercoagulability in COVID-19 is fibrin-mediated, but also highlights the important role that vWF may play in the genesis of thromboses in the pathophysiology of COVID-19. Interventions designed to enhance fibrinolysis might prove to be useful adjuncts in the treatment of coagulopathy in a subset of COVID-19 patients.</description><identifier>ISSN: 0925-5710</identifier><identifier>ISSN: 1865-3774</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-022-03437-2</identifier><identifier>PMID: 35994163</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Biomarkers ; Blood Coagulation Disorders - etiology ; Coagulation ; Complications ; Coronaviruses ; COVID-19 ; COVID-19 - complications ; Fibrin ; Fibrinogen ; Fibrinolysis ; Hematology ; Humans ; Inhibitors ; Interleukin-1 Receptor-Like 1 Protein ; Medicine ; Medicine & Public Health ; Oncology ; Original ; Original Article ; Pathophysiology ; Plasma levels ; Plasminogen activator inhibitors ; Survival ; t-Plasminogen activator ; Thromboembolism ; Thrombophilia - complications ; Thrombosis ; Thrombosis - etiology ; Tissue Plasminogen Activator ; Viral diseases ; Von Willebrand factor</subject><ispartof>International journal of hematology, 2022-12, Vol.116 (6), p.937-946</ispartof><rights>Japanese Society of Hematology 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. Japanese Society of Hematology.</rights><rights>Japanese Society of Hematology 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-f79bcdffff3ceebe228f0e5b39cd0ecb1250ed8febaac6d028999463b45f2b603</citedby><cites>FETCH-LOGICAL-c498t-f79bcdffff3ceebe228f0e5b39cd0ecb1250ed8febaac6d028999463b45f2b603</cites><orcidid>0000-0002-8980-9476</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-022-03437-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-022-03437-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35994163$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cabrera-Garcia, David</creatorcontrib><creatorcontrib>Miltiades, Andrea</creatorcontrib><creatorcontrib>Yim, Peter</creatorcontrib><creatorcontrib>Parsons, Samantha</creatorcontrib><creatorcontrib>Elisman, Katerina</creatorcontrib><creatorcontrib>Mansouri, Mohammad Taghi</creatorcontrib><creatorcontrib>Wagener, Gebhard</creatorcontrib><creatorcontrib>Harrison, Neil L.</creatorcontrib><title>Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Severe coronavirus disease-19 (COVID-19) has been associated with fibrin-mediated hypercoagulability and thromboembolic complications. To evaluate potential biomarkers of coagulopathy and disease severity in COVID-19, we measured plasma levels of eight biomarkers potentially associated with coagulation, fibrinolysis, and platelet function in 43 controls and 63 COVID-19 patients, including 47 patients admitted to the intensive care unit (ICU) and 16 non-ICU patients. COVID-19 patients showed significantly elevated levels of fibrinogen, tissue plasminogen activator (t-PA), and its inhibitor plasminogen activation inhibitor 1 (PAI-1), as well as ST2 (the receptor for interleukin-33) and von Willebrand factor (vWF) compared to the control group. We found that higher levels of t-PA, ST2, and vWF at the time of admission were associated with lower survival rates, and that thrombotic events were more frequent in patients with initial higher levels of vWF. These results support a predictive role of specific biomarkers such as t-PA and vWF in the pathophysiology of COVID-19. The data provide support for the case that hypercoagulability in COVID-19 is fibrin-mediated, but also highlights the important role that vWF may play in the genesis of thromboses in the pathophysiology of COVID-19. Interventions designed to enhance fibrinolysis might prove to be useful adjuncts in the treatment of coagulopathy in a subset of COVID-19 patients.</description><subject>Biomarkers</subject><subject>Blood Coagulation Disorders - etiology</subject><subject>Coagulation</subject><subject>Complications</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>Fibrin</subject><subject>Fibrinogen</subject><subject>Fibrinolysis</subject><subject>Hematology</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Interleukin-1 Receptor-Like 1 Protein</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Pathophysiology</subject><subject>Plasma levels</subject><subject>Plasminogen activator inhibitors</subject><subject>Survival</subject><subject>t-Plasminogen activator</subject><subject>Thromboembolism</subject><subject>Thrombophilia - complications</subject><subject>Thrombosis</subject><subject>Thrombosis - etiology</subject><subject>Tissue Plasminogen Activator</subject><subject>Viral diseases</subject><subject>Von Willebrand factor</subject><issn>0925-5710</issn><issn>1865-3774</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU1v1DAQhi0EosvCH-CALHHhEhjbcRxfkNDyValSOQAXDpbtOF2XJF48yaL21-NlS_k44IsP88zM-85LyGMGzxmAeoGMs1ZWwHkFohaq4nfIirWNrIRS9V2yAs1lJRWDE_IA8RKAKajVfXIipNY1a8SKfPkwWBwtdTGNNn8NGalFTD7aOXT0e5y3FJe8j3s7UDt1dN7mNLqEEWmc6DbhLs52iNcF3px_Pn1dMU13do5hmvEhudfbAcOjm39NPr1983Hzvjo7f3e6eXVW-Vq3c9Ur7XzXlyd8CC5w3vYQpBPadxC8Y1xC6No-OGt90wFvdVHfCFfLnrsGxJq8PM7dLW4MnS-7sx3MLsdi6cokG83flSluzUXaGy20bMvl1uTZzYCcvi0BZzNG9GEY7BTSgoYrkEI3mh3Qp_-gl2nJU7Fnii6AulGaF4ofKZ8TYg79rRgG5pCdOWZnSnbmZ3bm0PTkTxu3Lb_CKoA4AlhK00XIv3f_Z-wPBS2nXQ</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Cabrera-Garcia, David</creator><creator>Miltiades, Andrea</creator><creator>Yim, Peter</creator><creator>Parsons, Samantha</creator><creator>Elisman, Katerina</creator><creator>Mansouri, Mohammad Taghi</creator><creator>Wagener, Gebhard</creator><creator>Harrison, Neil L.</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8980-9476</orcidid></search><sort><creationdate>20221201</creationdate><title>Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients</title><author>Cabrera-Garcia, David ; Miltiades, Andrea ; Yim, Peter ; Parsons, Samantha ; Elisman, Katerina ; Mansouri, Mohammad Taghi ; Wagener, Gebhard ; Harrison, Neil L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-f79bcdffff3ceebe228f0e5b39cd0ecb1250ed8febaac6d028999463b45f2b603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Blood Coagulation Disorders - etiology</topic><topic>Coagulation</topic><topic>Complications</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>Fibrin</topic><topic>Fibrinogen</topic><topic>Fibrinolysis</topic><topic>Hematology</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Interleukin-1 Receptor-Like 1 Protein</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Pathophysiology</topic><topic>Plasma levels</topic><topic>Plasminogen activator inhibitors</topic><topic>Survival</topic><topic>t-Plasminogen activator</topic><topic>Thromboembolism</topic><topic>Thrombophilia - complications</topic><topic>Thrombosis</topic><topic>Thrombosis - etiology</topic><topic>Tissue Plasminogen Activator</topic><topic>Viral diseases</topic><topic>Von Willebrand factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cabrera-Garcia, David</creatorcontrib><creatorcontrib>Miltiades, Andrea</creatorcontrib><creatorcontrib>Yim, Peter</creatorcontrib><creatorcontrib>Parsons, Samantha</creatorcontrib><creatorcontrib>Elisman, Katerina</creatorcontrib><creatorcontrib>Mansouri, Mohammad Taghi</creatorcontrib><creatorcontrib>Wagener, Gebhard</creatorcontrib><creatorcontrib>Harrison, Neil L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cabrera-Garcia, David</au><au>Miltiades, Andrea</au><au>Yim, Peter</au><au>Parsons, Samantha</au><au>Elisman, Katerina</au><au>Mansouri, Mohammad Taghi</au><au>Wagener, Gebhard</au><au>Harrison, Neil L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>116</volume><issue>6</issue><spage>937</spage><epage>946</epage><pages>937-946</pages><issn>0925-5710</issn><issn>1865-3774</issn><eissn>1865-3774</eissn><abstract>Severe coronavirus disease-19 (COVID-19) has been associated with fibrin-mediated hypercoagulability and thromboembolic complications. To evaluate potential biomarkers of coagulopathy and disease severity in COVID-19, we measured plasma levels of eight biomarkers potentially associated with coagulation, fibrinolysis, and platelet function in 43 controls and 63 COVID-19 patients, including 47 patients admitted to the intensive care unit (ICU) and 16 non-ICU patients. COVID-19 patients showed significantly elevated levels of fibrinogen, tissue plasminogen activator (t-PA), and its inhibitor plasminogen activation inhibitor 1 (PAI-1), as well as ST2 (the receptor for interleukin-33) and von Willebrand factor (vWF) compared to the control group. We found that higher levels of t-PA, ST2, and vWF at the time of admission were associated with lower survival rates, and that thrombotic events were more frequent in patients with initial higher levels of vWF. These results support a predictive role of specific biomarkers such as t-PA and vWF in the pathophysiology of COVID-19. The data provide support for the case that hypercoagulability in COVID-19 is fibrin-mediated, but also highlights the important role that vWF may play in the genesis of thromboses in the pathophysiology of COVID-19. Interventions designed to enhance fibrinolysis might prove to be useful adjuncts in the treatment of coagulopathy in a subset of COVID-19 patients.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>35994163</pmid><doi>10.1007/s12185-022-03437-2</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-8980-9476</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2022-12, Vol.116 (6), p.937-946 |
| issn | 0925-5710 1865-3774 1865-3774 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9395834 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Biomarkers Blood Coagulation Disorders - etiology Coagulation Complications Coronaviruses COVID-19 COVID-19 - complications Fibrin Fibrinogen Fibrinolysis Hematology Humans Inhibitors Interleukin-1 Receptor-Like 1 Protein Medicine Medicine & Public Health Oncology Original Original Article Pathophysiology Plasma levels Plasminogen activator inhibitors Survival t-Plasminogen activator Thromboembolism Thrombophilia - complications Thrombosis Thrombosis - etiology Tissue Plasminogen Activator Viral diseases Von Willebrand factor |
| title | Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T18%3A48%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20biomarkers%20associated%20with%20survival%20and%20thrombosis%20in%20hospitalized%20COVID-19%20patients&rft.jtitle=International%20journal%20of%20hematology&rft.au=Cabrera-Garcia,%20David&rft.date=2022-12-01&rft.volume=116&rft.issue=6&rft.spage=937&rft.epage=946&rft.pages=937-946&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-022-03437-2&rft_dat=%3Cproquest_pubme%3E2890046792%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2890046792&rft_id=info:pmid/35994163&rfr_iscdi=true |